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Molecular  Cloning of cDNA Encoding  a  Novel  Platelet-Endothelial  Cell 
Tetra-Span  Antigen,  PETA-3 
By Stephen Fitter, Tim J. Tetaz,  Michael C. Berndt,  and  Leonie K. Ashman 
Platelet-endothelial cell tetra-span antigen (PETA-3) was 
originally identified as a novel human platelet surface  glyco- 
protein, 9~2327. which was detected by a monoclonal antibody 
(MoAb),  14A2.HI. Although this glycoprotein is present in 
low abundance on the platelet surface, MoAb  14A2.HI stim- 
ulates platelet aggregation and mediator release. We  now 
report isolation of a cDNA clone encoding PETA-3 from a 
library derived from  the megakaryoblastic leukemia cell line 
M07e. The clone encodes an open reading frame of 253 
amino acids that displays  25% to 30% amino acid  sequence 
identity with several members of the newly defined Tet- 
raspan, or Transmembrane 4 superfamily. These proteins 
consist  of four conserved putative transmembrane domains 
M ONOCLONAL ANTIBODIES (MoAbs) have  been used extensively to identify novel cell surface pro- 
teins and to investigate their functions. We previously de- 
scribed a murine  IgCl  MoAb,  14A2.H1, which bound to a 
27-kD glycoprotein  (gp27) that  is  present in human  platelet 
and  endothelial cell membranes, but is absent from  the ma- 
jority of leukocytes.' MoAb 14A2.Hl was studied in the 
Fourth and Fifth  International Leukocyte  Typing workshops 
and was found in both cases to be unique.*-' Of particular 
interest, this MoAb was shown to be capable of bringing 
about platelet aggregation and mediator release.' Recently 
we showed  that  MoAb  14A2.Hl synergizes with subthresh- 
old  doses of other agonists,  ADP,  adrenaline, collagen,  and 
serotonin  in mediating platelet activation.' 
As with certain other  MoAbs with  platelet  activating  abil- 
ity,  for  example  CD9  MoAbs,6 platelet  aggregation  induced 
by 14A2.HI was  shown  to  be  dependent  on binding by both 
the  Fc  region and  the  Fab region.'.s This  implies that signal- 
ling  may be mediated,  at  least in part, by FcyRII. Neverthe- 
less, a MoAb is not capable of extensive cross-linking of 
FcyRII (as is aggregated IgG) and, therefore, the specific 
antigen  may contribute  to the  signalling  process. Consistent 
with this, F(ab'),  fragments of a CD9  MoAb, together  with 
goat antimouse Ig coupled to latex beads, were shown to 
bring  about platelet  aggregation and mediator r e l e a ~ e . ~  
We  have now cloned  the  cDNA  encoding  gp27,  and 
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with a large divergent extracellular loop between  the third 
and fourth membrane-spanning regions.  PETA-3  has a single 
consensus sequence for N-linked glycosylation located in 
this extracellular loop. A single  PETA-3 RNA transcript (1.6 
kb) was detected in RNA isolated from M07e cells, bone 
marrow stromal cells, the C11 endothelial cell line, and sev- 
eral myeloid leukemia cell  lines. No transcript was detected 
in  the lymphoblastoid cell lines MOLT-4 and BALM-1. This 
pattern correlates well with previous protein expression 
data. Northern blot analysis  of RNA from a range of human 
tissues indicated that the transcript was present in most 
tissues, the notable exception being brain. 
0 1995 by The American Society of Hematology. 
shown it to be a novel member of the Transmembrane 4 
superfamily (TM4SF),  also  known as TetraspamX  This is  a 
family of cell  surface proteins characterized by four trans- 
membrane spanning  regions and includes other platelet and 
endothelial cell membrane proteins,  namely CD9  and  CD63. 
Hence, we have coined the name Platelet-Endothelial cell 
Tetra-span Antigen-3 (PETA-3) for gp27. While their pre- 
cise  functions  are  unknown,  the  TM4SF molecules appear  to 
be part of multicomponent signalling complexes that affect  a 
variety of cell adhesion, proliferation, and migration func- 
tions. 
MATERIALS AND METHODS 
Cell cdture. The human myelomonocytic cell line RC-2a. the 
T-cell  acute  lymphocytic  leukemia  (T-ALL)-derived cell line Molt- 
4, the B-lymphoblastoid cell line BALM-l, the  acute  promyelocytic 
leukemia cell line HL-60, the erythroleukemia cell line HEL900, 
and African Green Monkey derived COS cells were cultured in 
RPM1 1640 medium  supplemented  with 10% fetal calf  serum  (FCS). 
The human megakaryoblastic cell line M07e was cultured in Dul- 
becco's modified Eagle's  medium  (DMEM)  supplemented with 10% 
FCS and interleukin (IL)-3 ( I O  ng/mL). The murine tibroblastoid 
cell line L t k ~  was cultured in Ham's F12 medium supplemented 
with 1 0 %  FCS. The genomic transfectant T33.8" was cultured in  
Ham's  F12  supplemented with 10%- FCS  and  hypoxanthine- 
aminopterin-thymidine  (HAT). 
Purijication and sequencing of gp27. Cp27 was purified from 
the membrane glycoprotein fraction of platelets as previously de- 
scribed.' Purified gp27 (10 to 20  pg) was electrophoresed  on  a 1 0 %  
sodium dodecyl sulfate (SDS) polyacrylamide gel. After staining 
with Coomassie Brilliant blue, destaining, and extensive washing 
with water, the 27-kD band was excised, dried, and digested in 
situ with 2 p g  of modified trypsin (Promega, Madison, Wl). After 
overnight  incubation  at 37°C. tryptic  peptides  were  eluted  from  thc 
gel and  chromatographed on a  microbore  reversed-phase  high perfor- 
mance  liquid  chromatography  (HPLC)  column  (RP300,  C8, 1.0 mm 
I.D. x SO mm) as previously described,"' except that the gradient 
was extended to IS0 minutes and HCI (0.1 %) used as the mobile 
phase modifier. Peaks were collected manually, reduced with 8- 
mercaptoethanol in 0.1 mol/L NH,HC03 (pH 8.0) and rechromato- 
graphed under similar conditions, except that the temperature was 
increased  to 50T,  the  gradient  extended  to I80 minutes. and trifluo- 
roacetic acid (TFA, 0.1%) was used as the mobile phase modifier. 
Peaks collected from this second chromatographic separation were 
sequenced as previously  described."' 
Synthesis  and  cloning oj' rever.se trun.scriptuse-pol~mermse choirr 
reaction products. First strand cDNA was synthesized from I p g  
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Table 1. gp27 Partial Peptide Sequence  and  Corresponding DNA Sequence 
S e q u e n c e  o f  gp27 t r y p t i c   f r a g m e n t s   a n d   e x t r a p o l a t e d   P C R a m p l i f i c a t i o n   p r i m e r s *  
( Y )  ( h )  ~ P G H E A V T S A V ( X ) ~ L ~ Q E F  ( r )  
5 '  C A R   C C N   G G N   C A Y   G A R  GC 3 '  3' G T Y   R A N G T Y G T Y C T Y A A  5 '  
S e q u e n c e   o f   c l o n e d   R T - P C R p r o d u c t s   a m p l i f i e d   f r o m M 0 7 e   c D N A w i t h   d e g e n e r a t e   p r i m e r s t  
P C 1  5 '  C A A C C T  GGT CAT GAG GCT GTG ACC AGC GCT GTG GAC CAGCTT CAG CAG GAG TT 
P C 2  5 '  C A A C C T  G G G C A T G A G G C T  G T G A C C A G C  G C T  G T G G A C  C A G C T G C A G C A G G A G T T  




* R = A + G ; Y = T + C ; B = C + G + T ; N = A + G + C + T .  
t RT-PCR products were generated and sequenced as described in Materials  and Methods. 
of M07e poly (A+) RNA  using a First Strand cDNA Synthesis kit 
(Pharmacia, Piscataway, NJ). The buffer composition was adjusted 
to that recommended for optimal AmpliTaq activity (Perkin Elmer, 
Norwalk, CT) and 128-fold degenerate oligonucleotides, corre- 
sponding to the partial peptide sequence (Table l ) ,  were added to  a 
final concentration of SO nmoVL. The volume was adjusted to 70 
pL, and 2.5 U of AmpliTaq (Perkin Elmer) was added before thermal 
cycling ( I  minute at 94T ,  2 minutes at 40°C 2 minutes at 72°C) 
for 30 cycles. The oligonucleotide concentration was then increased 
to IO pmol/L, and 3 p L  of IO X polymerase chain reaction (PCR) 
buffer (Perkin Elmer) and a further 2.5 U of AmpliTaq were added. 
The reaction volume was adjusted to 100 pL, and a further 30 
amplification cycles were performed under the previous conditions. 
Amplified products corresponding to S3 bp were purified from a 6% 
acrylamide gel then cloned into a  T vector constructed in pBluescript 
KS(+). Recombinant clones were identified, then sequenced ac- 
cording to the dideoxy method," with T7 polymerase (Pharmacia) 
and a Superbase Reagent Sequencing Kit (Bresatec, Adelaide, Aus- 
tralia). 
cDNA library construction and screening. Clone pc2 was used 
to screen a commercially prepared HL-60 cDNA library made in 
AZAP I1 vector (Stratagene, La Jolla, CA). Approximately IO' 
plaques from this library were screened using plaque lift hybridiza- 
tion." After three cycles of plaque purification, a single positive 
clone was obtained. The pBluescript SK(-) from this clone was 
rescued according to instructions supplied by the manufacturer. The 
800-bp insert from this clone was then used  to screen a cDNA library 
constructed from 2 pgs of M07e poly (A+) RNA, in pBluescript 
KS(+) (Stratagene), using the Time Saver cDNA synthesis kit (Phar- 
macia) essentially as described by the manufacturer. Colonies corre- 
sponding to positive signals were retrieved and secondary and ter- 
tiary screenings performed. Positive clones were then subjected to 
nested deletion analysis using the Erase-a Base Exonuclease kit 
(Promega) and sequence determined for both strands. Deletion 
clones were sequenced with vector-specific T3 and T7 primers as 
described above. 
RNA isolation and analysis. Poly (A+) RNA was isolated from 
cultured cells as described elsewhere." A total of 1.5 pg of poly 
(A+) RNA  and 10 pg of total RNA were fractionated by electropho- 
resis in a 1% agarose-formaldehyde gel, transferred to Hybond N+ 
nylon membrane (Amersham, Arlington Heights, IL), cross-linked 
at 0.45 J/cmZ (Hybaid cross-linker), then hybridized to probes la- 
belled with [(u-~*P]-~ATP by random priming using the Klenow 
fragment of DNA polymerase I.'* Commercially obtained human 
multiple tissue Poly (A+) RNA blots (Clontech) were used (see Fig 
SC and D). Filters were prehybridized at 42°C in SO% formamide, 
6X SSC, 5X Denhardts, 0.1% SDS, 10 mmol/L Hepes pH 7.2, 1 
mmol/L EDTA pH 7.2, 2 mmol/L sodium pyrophosphate pH 7.2, 
160 pg/mL heat-denatured salmon sperm DNA and SO pg/mL tRNA 
for 2 2  hours. Filters were probed (24 hours) in fresh buffer with 
10' cpm/mL of labelled probe. Stringency washes were performed 
in 0.1 X SSC + 0.1 % SDS at RT followed by two 30-minute washes 
at 60°C. The PETA-3 probe was the 1.45-kb EcoRI fragment 
from pGP27.1. The glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) probe was a 780-bp fragment from pHcGAP (ATCC, 
Rockville, MD). 
Transient transfection of COS cells. The 1.45-kb EcoRI frag- 
ment from pGP27.1 was subcloned into the eukaryotic expression 
vector pcDNA-l (Invitrogen, San Diego, CA) in both sense and 
antisense orientations according to standard protocols.'* COS cells 
from a confluent 75 cm2 flask  were harvested by incubation with 1 
mmol/L  EDTA for 5 minutes in 5% CO, at  37°C. Cells were  washed 
three times in MTPBS (SO mmol/L NaCI, 16 mmoVL Na2HP04, 4 
mmol/L NaH,P04, 2H,O, pH 7.3), then resuspended in 800 pL of 
MTPBS. DNA (10 pg) was added, mixed by gentle pipetting, and 
the suspension was transferred to a 0.4-cm electroporation cuvette 
(Bio-Rad, Hercules, CA) on ice. After I O  minutes, the cellDNA 
mix  was electroporated at S O 0  pFd capacitance and 0.3 kV voltage 
using a Biorad Genepulser coupled to a capacitance extender. Elec- 
troporated cells were  mixed  with 1 mL of  RPM1 + 10% FCS, 
overlayed on 1 mL 100% FCS, and pelleted by centrifugation at 
200g for 5 minutes. Lysed cells and FCS were aspirated and the 
transfected cells were then resuspended in 20 mL of medium and 
used  to  reseed a 75 cm* flask. After a 72-hour incubation (S% CO,, 
37°C). S X lo4 cells were cytocentrifuged onto glass slides, fixed 
for 30 seconds in buffered formol acetone, and subjected to immuno- 
histochemical staining by the alkaline phosphatase antialkaline phos- 
phatase (APAAP) method using MoAb 14A2.H1, as previously de- 
scribed.' 
RESULTS 
Generation of PETA-3 cDNA probe. Immunoaffinity  pu- 
rified  gp27  was  subjected  to  trypsin  digestion and two  inde- 
pendent  peptides  were  sequenced.  Both  fragments  contained 
identical sequences (Table 1). The high degree of coding 
redundancy  and  the  undefined  amino acid in  the  central  por- 
tion of the peptide precluded direct screening of a cDNA 
library using degenerate oligonucleotides. Instead,  fully  de- 
generate oligonucleotides, based on the partial amino acid 
sequence, were synthesized  to  allow PCR  amplification 
across the peptide sequence generating a 53-bp fragment. 
RNA  was  isolated  from the  megakaryoblastic cell line 
M07e, which  expresses abundant  PETA-3  (data  not shown), 
and first strand cDNA was synthesized using oligo(dt)12-,8. 
PCR  amplification  was  then  performed using the  degenerate 
primers (Table 1) and amplified products corresponding to 
53 bp  were cloned and sequenced. The sequence of the 
cloned products  accurately  predicted  the  intervening  amino 
acids confirming the cloned products as corresponding to 
gp27 (Table 1). Differences between the cloned products 
corresponded  to  positions of degeneracy  within  the  oligonu- 
cleotide primers. From the sequences,  amino  acid  "x"  was 
For personal use only.on January 17, 2017. by guest  www.bloodjournal.orgFrom 
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determined to be aspartic acid, and this was confirmed on 
reanalysis of  the sequencing HPLC profiles. 
Isolation of PETA-3  cDNA clones. Clone pc2 (Table 1) 
was selected for library screening based on codon usage 
data.14 Initially, IO6 recombinant phage from a HL-60 cDNA 
library  in G A P  I1 vector were screened. After three cycles 
of plaque purification, a single positive clone was  obtained. 
The rescued  plasmid contained an  800-bp insert, which  was 
truncated at the 5' end (data not shown). Given the low 
representation of PETA-3 transcripts in this library, a M07e 
cDNA library in pBluescript KS(+) was constructed and 
screened  with the 800-bp HL-60 gp27 clone. From the pri- 
mary screen, 20 clones were isolated, of which 10 were 
further purified following secondary and tertiary screenings. 
On EcoRI digestion, these clones liberated inserts ranging 
from l to 1.5 kb. The clone with the most 5' sequence was 
determined  (pGP27.1)  and further characterized. 
Primary structure analysis of PETA-3. The cDNA se- 
quence shown in Fig 1 is derived from two overlapping 
clones, pGP27.1,  which spans bases  1 to 1443 and  pGP27.2, 







































Fig 1. Nucleotide sequence and deduced amino 
acid wquonce of PETA-3. The cDNA sequence is 
shown  above  tho  deduced  emino  acid  sequence.  Nu- 
cleotide reddues are numbered above and amino 
acid residws bolow.  The  partial p.ptid. sequence is 
undorlined. A poasible N-glycosylation site is indi- 
cated  by a broken  underline,  while a possible polyed- 
enyiation  sequence  is  double  underlined. 
sequence showed  a single open reading frame of 253 amino 
acids with the partial amino acid sequence in frame at  posi- 
tions 134-153. The partial peptide sequence is flanked by 
an arginine residue at position 133, indicative of a trypsin 
recognition sequence. The deduced  protein  molecular  weight 
of 28 kD is slightly larger than  that observed on  nonreduced 
SDS-polyacrylamide gel electrophoresis (PAGE) gels.' A 
potential asparagine-linked glycosylation site is located at 
residue  159. The 5' proximal  ATG codon, at  position  20, is 
in  good context for initiation of translation." The in frame 
TGA stop codon is followed by a 636-bp noncoding se- 
quence containing a potential polyadenylation signai (AT- 
TAAA), and a  poly(A) tail. Hydrophobicity plot analysis16 
of the putative gp27 coding region (Fig 2) indicates four 
groupings of hydrophobic residues, three at the amino  termi- 
nus and one at the carboxyl terminus. Each hydrophobic 
grouping contains 222  amino acids, sufficient to represent 
membrane spanning domains. The putative transmembrane 
domains I, D, and III (Fig 2) are separated by short hydro- 
philic regions, whereas domains In and IV are  separated by 
a large, mostly hydrophilic, grouping. The amino terminus 
For personal use only.on January 17, 2017. by guest  www.bloodjournal.orgFrom 




Fig 2. Hydrophobicity plot of the deduced  amino 
acid  sequence of ETA-3, CW, and CD63. Plots  were 
determined by the method described by Kyte and 
Dooliile.’6 Hydrophobic residues are positive. I-IV 
indicate  putative  transmembrane  domains.  Arrows 
indicate  potential  glycosylation sites. 
consists of 16 mostly hydrophilic residues and the carboxyl 
terminus seven hydrophilic residues, suggesting either an 
intra or extracellular location for both ends of the molecule. 
No signal peptide consensus motif was found at the amino 
terminus, consistent with it remaining within the cytoplasm. 
Homology to PETA-3. Sequence alignment and homology 
computations  were  performed at the National  Centre for Bio- 
technology  Information  (NCBI,  Bethesda, MD) by use of  the 
BLAST  Network  service.”  Results from these  searches  indi- 
cated  that  PETA-3  showed  25% to 30% amino acid  sequence 
identity to several members of the newly defined transmem- 
brane  4 (TM4SF) superfamily: These  molecules  include 
(25%),  CD5322  (29%), RUC33 (CD82)23  (28%),  TAPA-1 
(CD81)% (26%), C0-02925 (27%),  SM2326  (23%),  and A15” 
(29%).  These  molecules are structurally  related  and  character- 
ized  by the  presence of four putative  transmembrane  domains.’ 
Comparison  of  hydrophobicity plots of PETA-3  with  CD9  and 
CD63 (Fig 2) clearly demonstrates these proposed domains 
based on groupings of hydrophobic amino acids. An amino 
acid  sequence  alignment of PETA-3  with  CD9  and  CD63  (Fig 
3)  suggests  conservation of the  secondary  structure by the  pres- 
ence of seven  conserved  cysteine  residues.  Assignment of do- 
mains  based on hydropathicity  of these  molecules  shows  that 
homology  is  primarily  found in the transmembrane  domains. 
In particular,  PETA-3  shows  a  high  degree of sequence  identity 
to CD9 in transmembrane  domains I and IV (Fig  3).  Several 
consensus  motifs  have  been suggested for TM4SF  mole- 
cules.828  The  CCG,  PXSC,  and  EGC  motifs ( n the large  extra- 
cellular  domain), are clearly  defined  for  PETA-3  at  positions 
156,181, and 205 (Fig 1). The  larger motif GCXAXXXEXXN 
(between Th4 domains  1  and  2),  which  corresponds to amino 
acids  78-88  (Fig l), differed  in  two  positions. 
pGP27.1 encodes PETA-3. To confirm pGP27.1 as the 
construct encoding PETA-3, pGP27.1 cDNA was subcloned 
into the eukaryotic expression vector pcDNA-l and a tran- 
sient transfection was performed in African Green Monkey- 
derived COS cells (Fig 4). Expression of the antigen was 
c~9I8.19 (30%  sequence  identity),  CD6320  (29%),  CD37” 
detected by the APAAP staining technique using the anti- 
PETA-3 MoAb 14A2.Hl. Antibody-dependent staining was 
observed in cells transfected with the sense construct (Fig 
4B), but not the antisense construct (Fig 4A). 
Northern blot analysis. Expression of PETA-3 mRNA 
was examined by Northern blot analysis of RNA isolated 
from various human cell lines, a murine L cell transfectant, 
bone marrow stroma, a spontaneous human umbilical vein 
endothelial cell (HUVEC) cell line, C l  and adult human 
tissues. A single mRNA species (1.6 kb) was detected in 
RNA isolated from M07e, HL-60, HEL900, and  RC-2a  hu- 
man cell lines (Fig 5).  No detectable signal was observed in 
RNA isolated from lymphoblastoid cell lines MOLT-4 and 
BALM-l, which correlates with previous protein expression 
data.’ A single transcript, also of 1.6 kb, was observed in 
RNA isolated from the murine L cell transfectant T33.8  that 
was produced by human genomic DNA transfection and 
isolation with MoAb 14A2.H1.9 This transcript was absent 
from nontransfected parent cells. A strong PETA-3 signal 
was observed in RNA isolated from TNFcr-treated  bone  mar- 
row stroma and the spontaneous HUVEC cell line C1 l. RNA 
isolated from C11 cells treated with cyclosporin A and/or 
TNFcr did not appear to have altered levels of PETA-3 tran- 
scripts. A single RNA species of 1.6  kb was also observed 
in most human adult tissue (Fig 5C  and  D).  High levels of 
PETA-3 transcript were observed in  RNA isolated from 
heart, lung, pancreas, and prostate tissue. Low levels were 
observed in hematopoetic tissues including spleen, thymus, 
and peripheral blood leukocytes, and  only negligible levels 
were detected in brain tissue. 
DISCUSSION 
We report here the molecular cloning of a cDNA encoding 
a new member of the TM4SF, PETA-3. The protein, pre- 
viously termed gp27, was originally identified using the 
MoAb 14A2.H1, and the approach used here was to purify 
protein from a platelet glycoprotein extract, obtain partial 
amino acid sequence, and to use an oligonucleotide probe 
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F I T E R  ET AL 
Fig 3. Amino  acid  sequence 
alignment of PETA-3, CD9, and 
CD63 antigens.  The  multiple se- 
formed using MACAW by the 
quence alignment  was  per- 
method of Schuler et aI?* Amino 
acids  for  all  three  molecules  are 
numbered  on  the  right. The  lines 
above the sequence  represent 
the  putative  transmembrane  do- 
mains, which are  labeled I-W. 
Residues  homologous t o  PETA- 
3 were determined; upper case 
represents  residues  conserved 
between  all  three molecules; 
lower case between PETA-3 and 
CD9; conserved  cysteine  resi- 
dues  are in bold  type. 
to screen  a cDNA library from M07e megakaryoblastic  leu- Northern blot of RNA isolated  from a murine L cell subline. 
kemia  cells.  Several lines of evidence indicate  that the cloned T33.8. expressing  gp27 after  transfection with human  geno- 
cDNA  encodes the  antigen. Firstly. the deduced  amino acid mic DNA." but not in untransfected cells (Fig S ) .  Finally. 
sequence includes  the  partial  peptide sequence obtained from surface expression  of the antigen was detected  using MoAb 
immunoaffinity purified gp27  (Fig 1 ). Secondly, a band cor- 14A2.H I ,  following  transfection  of  the cDNA into COS cells 
responding to the native gp27 transcript was detected in a (Fig  4). 
B 
Fig 4. Detection of PETA-3 in transfected COS 
cells by APAAP. Cells were transfected with the 
pcDNA-l  vector  containing  PETAJ  cDNA in the  anti- 
sense  (A) or sense IBI orientation.  Transfected  cells 
were  incubated with MoAb  14AZH1  and  three cycles 
of  incubation with rabbit  antibody t o  mouse  immu- 
noglobulin,  then  mouse  monoclonal  anti-alkaline 
phosphatase  alkaline  phosphatase  soluble  com- 
plexes. After  incubation with Napthol  AS-MX  phos- 
phate  free  acid  substrate  and  Fast  Red TR salt  indica- 
tor,  smears  were  counterstained with hematoxylin. 
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Fig 5. Expression  of  PETA-3 
mRNA. Approximately 1.5 pgs 
poly (A') RNA, isolated from 
eight different cell lines (A), 10 
pgs of total RNA (B), and 2 pgs 
of poly (A') RNA (C and D) was 
analyzed by Northern blotting. 
Blots were sequentially hybrid- 
ized to PETA-3  (1.45-kb EcoRl 
fragment from pGP27.1) and 
glyceraldehyde-3-phosphate de- 
hydrogenase  (GAPDH)  probes. 
Where indicated (TNFalCSA; 
TNFa) cells were incubated with 
cyclosporin A (1 pmol/L) andlor 
tumor necrosis  factor a (100 U/ 
mL), respectively. 
A 
PETA-3 (I) - 0 0 
C 
PETA-3 0 -4 
GAPDH 
Computer aided analysis of the cDNA clone showed a 
long  open  reading frame of 253 amino  acids that encodes a 
core protein  of  molecular mass 28 kD. This is slightly  larger 
than that observed on nonreduced SDS  PAGE gels.'  possibly 
due  to  the hydrophobic  nature of the  protein and/or the pres- 
ence of several cysteine residues that may be involved in 
disulfide  bonding. Amino  acid  sequence homology and 
strong secondary structure similarities inferred from hydro- 
phobicity plots indicate that PETA-3 is a novel TM4SFX 
molecule.  Hydropathicity analysis of TM4SF molecules sug- 
gests they span  the membrane  four times. indicative  of Type 
111 integral membrane proteins.'" Membrane topology studies 
using CD81 (TAPA-I )3'  and epitope mapping experiments 
using  the  major  hydrophilic domain of murine CDS3" sup- 
port this  proposed structure  and predict that both the  amino 
and  carboxyl  termini lie inside  the  cell while the major hy- 
drophilic domain of these  molecules  is extracellular. PETA- 
3 has a single putative N-linked glycosylation site located 
in this  hydrophilic domain  and is known to be glycosylated 
by virtue of its binding to concanavalin  A-Sepharose.' 
B 







- ' W PETA-3 
GAPDH 
Using MoAb 14A2.H1, PETA-3  was originally identified 
as a novel platelet and endothelial cell antigen that has a 
restricted  pattern of expression in peripheral blood and vas- 
culature  similar to that of other  TM4SF members CD9  and 
CD63. CD63 is found in the dense granules of platelets" 
and the Weibel-Palade bodies of endothelial cells and is 
rapidly  mobilized to the  surface  on acti~ation:~' Like CD9.'' 
PETA-3 is constitutively expressed on the platelet surface. 
although at a  much lower copy  number. and  displays a  simi- 
lar pattern of expression on microvascular endothelium in  
tonsil sections.' Other TM4SF members, CD81 and C D 8 2  
are also present on platelets and/or endothelium. but are 
predominately lymphoid markers. while the expression of 
the  remaining  family  members  on  platelets and/or endothe- 
lium  has not been reported.".' Despite the restricted  distribu- 
tion of PETA-3 within the hematopoietic system (platelets 
and  their  precursors).  Northern blot analysis  presented here 
demonstrates that PETA-3 is widely  and  abundantly ex- 
pressed in different tissues. A notable exception was brain 
tissue. Further analysis will be required to determine the 
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particular cell types that display this protein. We previously 
observed that epithelial cells, as well as endothelium, in 
tonsil were positive by APAAP, and have now shown that 
bone  marrow stromal cells express PETA-3 mRNA  at  high 
levels. In  the Vth International Workshop on Human Leuco- 
cyte Differentiation Antigens, MoAb 14A2.Hl was found to 
bind to a wide range of cells of stromal type.’’ 
The biologic role of PETA-3 remains uncertain. While 
MoAb 14A2.HI acts as a platelet agonist, this appears to 
depend, at least in part, on signalling via the immunoglobulin 
Fc receptor FcyRII.’,’ Nevertheless, the low copy number 
of the protein on platelets (about lO’/platelet; similar to 
FcyRII), led us to postulate that PETA-3 may form a com- 
plex  with this receptor.’ While there is  no direct evidence for 
this proposal at present, other tetra-spans have been shown to 
be components of transmembrane signalling complexes. 
ADl, the rat homolog of CD63, has  been shown to closely 
associate with the high  affinity IgE receptor FctRI on baso- 
p h i l ~ , ~ ~  although the biologic significance of this association 
has not been determined. TAPA-1 (CD81) forms part of a 
signalling complex with CD21, CD19, and Leu-l3 on B 
~ e l l s , ~ ~ , ~ ~  and  with C33 and CD4 or CD8 on T cells.3y CD53 
is associated with CD2 on rat T cells and natural killer (NK) 
cells,40 and  with a complex of CD37, TAPA-I , CD82, and 
major histocompatibility complex (MHC) class I or I1 mole- 
cules in B cells.4’ It is interesting to note that these molecules 
can associate with different proteins in different cell types 
and  that complexes often contain more  than one member of 
the TM4SF. Homology between TM4SF members appears 
concentrated in the transmembrane domains. This has been 
suggested25 to indicate a common effector function, whereas 
the divergence of sequences in the large extracellular domain 
may determine specificity for protein-protein interactions. 
Consistent with this, dissection of CD2 l/CD19/TAPA- l /  
Leu- 13 complex on B cells using chimeric constructs showed 
that CD19 and TAPA-1 interact via their extracellular do- 
main~.’~ 
TM4SF members have been implicated in a wide range 
of biologic processes. MoAbs directed against TAPA- 1 and 
CD9 have been shown to cause homotypic adhesion of pre- 
B ~ e l l s . ~ ~ . ~ ’  MoAbs directed against CD9 have also been 
shown to augment neutrophil adherence to endothelium4 
and  to cause pre-B cell adherence to bone  marrow  fibroblast 
cells through induction or activation of fibronectin recep- 
t o r ~ . ~ ~  CD63 has recently been shown to colocalize with  von 
Willebrand factor (vWF) and P-selectin in Weibel-Palade 
bodies of endothelial cells,34 implicating CD63 in adhesion 
processes. It has also been suggested, based on structural 
considerations, that TM4SF members may be components 
of ligand-gated ion channels,x although evidence is lacking. 
Tetra-spans may also be involved in development and 
oncogenesis. CD9 was recently shown to be identical to 
Motility-Related Protein (MRP- 1). Transfection of cell lines 
with cDNA encoding CD9hlRP- 1 led to suppression of cell 
motility in vitro, and suppressed the metastatic potential of 
BL6 melanoma cells in vivo:‘ Furthermore, expression of 
this protein was recently shown to be inversely related to 
metastasis in human melan~rna.~’ However, some TM4SF 
proteins appear to be associated with transformation. CO- 
029, L6, and ME491 (CD63) have all been identified as 
tumor-associated  antigen^.*'.^'.^' Recently SAS, a gene am- 
plified in human sarcomas, was  identified as a new member 
of the TM4SF.’” PETA-3, like CD9, is expressed by some 
primary acute myeloid leukemia cells and cell lines, whereas 
these proteins are absent from normal myeloid progenitor 
cells, colony-forming unit-granulocyte macrophage (CFU- 
GM).” Whether these proteins play a role in leukemogenesis 
remains to  be determined. 
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